Anti-TB Drug Side-Effects on the Treatment of Drug-Resistant Tuberculosis (DR-TB) in dr. Zainoel Abidin Hospital Banda Aceh
DOI:
https://doi.org/10.36497/jri.45i1.507Keywords:
anti-tuberculosis drug, drug-resistant tuberculosis, side effectsAbstract
Background: Drug-resistant tuberculosis (DR-TB) is treated with second-line anti-tuberculosis (anti-TB) drugs which are comparatively less effective and more toxic. The increased toxicity of the drugs may lead to the occurrence of side effects throughout the treatment. The study aims to assess DR-TB patients' side effects and clinical profile at the dr. Zainoel Abidin Hospital, Banda Aceh.
Methods: Observational descriptive study of DR-TB patients who underwent treatment from 2020 to 2022 at dr. Zainoel Abidin Hospital, Banda Aceh. The data was taken from medical records of patients which are then analysed using univariate analysis.
Results: Out of 49 patients, most of them were male with 23 people (65,3%), belonging to the age group of 46-55 with 11 people (22,4%), worked as entrepreneurs with 11 people (22,4%), and most came from Banda Aceh and Aceh Besar with 14 people each (28,6%). Twenty-seven patients (65,1%) were suspected of secondary infection, most of which were cases of relapse from 10 people (20,4%). 39 of the patients (79,6%) had rifampicin-resistant tuberculosis. 36 patients (73,4%) were given individualized treatment with Lfx – Bdq – Lzd – Cfz – Cs being the most common drug combination given to 16 people (32.7%). All patients experienced side effects from the treatment, with the most common being nausea from 28 people (57,1%) followed by peripheral neuropathy from 19 people (38,8%).
Conclusion: Side effects are commonly found in the treatment of DR-TB and may become more prevalent as the treatment continues. Educating the patient and treating side effects is important to maintain patient compliance.
Downloads
References
1. Patterson B, Wood R. Is cough really necessary for TB transmission? Tuberculosis. 2019;117:31–5.
2. Direktorat Jenderal Pencegahan dan Pengendalian Penyakit (P2P) Kementerian Kesehatan Republik Indonesia. Petunjuk teknis penatalaksanaan tuberkulosis resistan obat di Indonesia. Indonesia; 2020. p. 1–4.
3. Siregar SR. Extensively drug resistant tuberculosis (XDR TB). AVERROUS: Jurnal Kedokteran dan Kesehatan Malikussaleh. 2019;5(2):26–43.
4. World Health Organization. Global tuberculosis report 2023. Geneva: World Health Organization; 2023.
5. World Health Organization. Global tuberculosis report 2020. Geneva: World Health Organization; 2020.
6. Adam MAM, Ali HMH, Khalil EAG. Initial second-line drug resistance of Mycobacterium tuberculosis isolates from Sudanese retreatment-patients. J Clin Tuberc Other Mycobact Dis. 2017;9:21–3.
7. Agrebi S, Ben Saad S, Habouria C, Daghfous H, Tritar F. Tolerance and side effects of second line anti tubercular drugs. 2017;50(suppl 61):PA2705.
8. Ganiyu AA, Avong YK, Akinyede A, Ige OM, El tayeb O, Taleatu F, et al. Prevalence of Adverse Drug Reactions to Second Line Anti Tuberculosis Drugs in Nigeria: A Cross-Sectional Study. J Tuberc Res. 2021;9(2):90–102.
9. Zhang Y, Wu S, Xia Y, Wang N, Zhou L, Wang J, et al. Adverse events associated with treatment of multidrug-resistant tuberculosis in China: An ambispective cohort study. Medical Science Monitor. 2017;23:2348–56.
10. Atif M, Sarwar MR, Azeem M, Umer D, Rauf A, Rasool A, et al. Assessment of WHO/INRUD core drug use indicators in two tertiary care hospitals of Bahawalpur, Punjab, Pakistan. J Pharm Policy Pract. 2016;9:27.
11. Massud A, Syed Sulaiman SA, Ahmad N, Shafqat M, Chiau Ming L, Khan AH. Frequency and management of adverse drug reactions among drug-resistant tuberculosis patients: Analysis from a prospective study. Front Pharmacol. 2022;13:883483.
12. Nilamsari WP, Rizqi MF, Regina NO, Wulaningrum PA, Fatmawati U. Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: A retrospective study. J Basic Clin Physiol Pharmacol. 2021;32(4):783–7.
13. Mukati S, Julka A, Varudkar HG, Singapurwala M, Agrawat JC, Bhandari D, et al. A study of clinical profile of cases of MDR-TB and evaluation of challenges faced in initiation of second line Anti tuberculosis treatment for MDR-TB cases admitted in drug resistance tuberculosis center. Indian Journal of Tuberculosis. 2019;66(3):358–63.
14. Rosdiana D, Anggraini D, Yovi I, Tasril M. Profil and evaluation of resistant tuberculosis drug’s side effect in diabetes and non diabetes mellitus patient at RSUD Arifin Achmad. Jurnal Respirologi Indonesia. 2020;40(3):156–62.
15. Tegegne BS, Mengesha MM, Teferra AA, Awoke MA, Habtewold TD. Association between diabetes mellitus and multi-drug-resistant tuberculosis: Evidence from a systematic review and meta-analysis. Syst Rev. 2018;7(1):161.
16. Saktiawati AMI, Subronto YW. Influence of diabetes mellitus on the development of multi drug resistant-tuberculosis in Yogyakarta. Acta Med Indones. 2018;50(1):11–7.
17. Tao N ning, He X chun, Zhang X xin, Liu Y, Yu C bao, Li H chen. Trends and characteristics of drug-resistant tuberculosis in rural Shandong, China. International Journal of Infectious Diseases. 2017;65:8–14.
18. Jung J, Jegal Y, Ki M, Shin YJ, Kim CT, Shim TS, et al. Characteristics of drug resistant tuberculosis in sanatoria of North Korea. J Korean Med Sci. 2017;32(7):1105–10.
19. Yang TW, Park HO, Jang HN, Yang JH, Kim SH, Moon SH, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea. Medicine (United States). 2017;96(28):e7482.
20. Törün T, Güngör G, Özmen İ, Bölükbaşı Y, Maden E, Bıçakçı B, et al. Side effects associated with the treatment of multidrug-resistant tuberculosis. International Union Against Tuberculosis and Lung Disease. 9(12):1373–7.
21. Fatmawati U, Kusmiati T. Characteristics and the side effects of new MDR-TB treatment in the Dr. Soetomo Hospital during 2016. Jurnal Respirasi. 2019;3(3):67–73.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Yunita Arliny, Muhammad Fadjar Muarif, Wilda Mahdani, Dewi Behtri Yanifitri
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
- The authors own the copyright of published articles. Nevertheless, Jurnal Respirologi Indonesia has the first-to-publish license for the publication material.
- Jurnal Respirologi Indonesia has the right to archive, change the format and republish published articles by presenting the authors’ names.
- Articles are published electronically for open access and online for educational, research, and archiving purposes. Jurnal Respirologi Indonesia is not responsible for any copyright issues that might emerge from using any article except for the previous three purposes.
